MetLife Investment Management
ORKA icon

MetLife Investment Management’s Oruka Therapeutics ORKA Stock Holding History

MetLife Investment Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.79M Buy
29,313
+7,950
+37% +$530K 0.01% 952
2026
Q1 		$1.05M Buy
21,363
+1
+0% +$35 0.01% 1373
2025
Q4 		$647K Buy
21,362
+4,849
+29% +$135K ﹤0.01% 1671
2025
Q3 		$318K Hold
16,513
– – ﹤0.01% 2048
2025
Q2 		$185K Buy
+16,513
New +$172K ﹤0.01% 2236

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MetLife Investment Management's ORKA Position: Q2 2026 in Review

MetLife Investment Management increased its Oruka Therapeutics (ORKA) stake by 37% in Q2 2026, buying an estimated $530K and bringing the position to 29,313 shares worth $2.79M. The position accounts for 0.01% of the portfolio, ranked #952.

MetLife Investment Management first reported a position in ORKA in Q2 2025 and has held it in 5 quarters since. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • MetLife Investment Management held 29,313 shares of Oruka Therapeutics worth $2.79M as of Q2 2026.
  • MetLife Investment Management bought 7,950 Oruka Therapeutics shares in Q2 2026, an estimated $530K.
  • Oruka Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #952 holding.
  • MetLife Investment Management first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.